Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration ○
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Myers Squibb
since
auto-detected in 8 stories
26 days ago
U.S. drugmaker Bristol Myers Squibb inked a partnership with a Chinese company that some say could mark the next wave of collaboration across continents.
4 months ago
Another alliance of health care and AI signals why pharma stocks should be back in favor ○
Bristol Myers Squibb and Microsoft's new partnership aimed at accelerating early detection of lung cancer.
8 months ago
Bristol Myers Squibb aligns UK and US prices for new schizophrenia drug ○
found
a story from Financial Times ✅ › Financial Times
Pharmaceutical companies are under pressure to lower prices on both sides of the Atlantic
10 months ago
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount ○
The companies' new effort would bypass traditional middlemen to cut the drug's monthly cost from a list price of around $606 to $346.
13 months ago
Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs ○
The guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not Trump's planned pharmaceutical tariffs.
Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs ○
The guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not Trump's planned pharmaceutical tariffs.
16 months ago
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance ○
The company also issued a 2025 guidance that fell short of expectations, as some of the company's older drugs face competition from cheaper generics.
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance ○
The company also issued a 2025 guidance that fell short of expectations, as some of the company's older drugs face competition from cheaper generics.
page 1 of 1